The Quantellect read.As of Nov 19, 2026, 6 active firms cover Belite Bio Inc ADR: 6 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $195.00 to $303.00, a moderate spread. The average target of $242.17 sits 55% above the current $156.24. The rating mix has held broadly steady over recent months.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy6100%
Neutral00%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$242.17
+55.0% upside
Average target across 6 active firms as of Nov 19, 2026 vs $156.24 current
Highest Target$303.00
Average Target$242.17
Lowest Target$195.00
Detailed analyst forecasts for BLTE
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 6 of 6 active firms rate BLTE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BLTE EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 3 analysts
Next period, 3 analysts expect Belite Bio Inc ADR to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-2.81, growing to $-1.24 the year after.
REVENUE · NEXT QUARTER
$120.0M
Range $0 – $185.0M · 3 analysts
Revenue is expected to reach $120.0M (range $0 – $185.0M). Full-year consensus is $0, rising to $264.1M next year.
Top analysts covering Belite Bio Inc ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BLTE.
#1
Graig Suvannavejh
Mizuho · Rank #239
Buy
$234.00+49.8% to target
Overall win rate
40%
+ Follow
#2
Marc Goodman
Leerink Partners · Rank #251
Buy
$85.00-45.6% to target
Overall win rate
46%
+ Follow
#3
Yi Chen
HC Wainwright & Co. · Rank #350
Buy
$245.00+56.8% to target
Overall win rate
34%
+ Follow
#4
WI
Whitney Ijem
Canaccord Genuity · Rank #392
Buy
$303.00+93.9% to target
Overall win rate
35%
+ Follow
#5
TA
Tazeen Ahmad
B of A Securities · Rank #411
Buy
$200.00+28.0% to target
Overall win rate
46%
+ Follow
BLTE stock forecast FAQ
What is BLTE's average 12-month price target?+
The 6 active firms with a live target average $242.17 for Belite Bio Inc ADR over the next 12 months, ranging from a $303.00 high to a $195.00 low, as of Nov 19, 2026.
Is BLTE stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BLTE?+
The Street-high target is $303.00 (Canaccord Genuity), and the Street-low is $195.00 (B of A Securities). The average of all 6 active-firm targets is $242.17.
How many active Wall Street firms cover BLTE?+
6 active firms have a recognized rating on Belite Bio Inc ADR as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BLTE?+
Among analysts who currently cover BLTE, Graig Suvannavejh of Mizuho has the strongest overall Quantellect track record (Rank #239). Their current call is Buy with a $234.00 target.
What is Belite Bio Inc ADR's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 3 analysts. Full-year EPS is projected at $-2.81, rising to $-1.24 the following year.
How much revenue is Belite Bio Inc ADR expected to report next quarter?+
Consensus revenue is $120.0M (range $0 – $185.0M). Full-year revenue is projected at $0, growing to $264.1M next year.
Have analysts been upgrading or downgrading BLTE lately?+
As of Nov 19, 2026, 6 of 6 active firms rate BLTE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BLTE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.